Exploring the Link between Plasma Levels of PCSK9, Immune Dysregulation and Atherosclerosis in Patients with Primary Sjögren’s Syndrome
Proprotein convertase subtilisin/kexin type 9 (PCSK9) regulates lipid metabolism contributing to cardiovascular (CV) risk in the general population. The relationship between PCSK9 and CV risk in systemic autoimmune diseases has been poorly explored. We investigated the association between plasma PCS...
Main Authors: | Vanessa Bianconi, Giacomo Cafaro, Massimo Raffaele Mannarino, Carlo Perricone, Elena Cosentini, Onelia Bistoni, Rita Paltriccia, Rita Lombardini, Roberto Gerli, Matteo Pirro, Elena Bartoloni |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2023-09-01
|
Series: | Biomolecules |
Subjects: | |
Online Access: | https://www.mdpi.com/2218-273X/13/9/1384 |
Similar Items
-
PCSK9 immunization using nanoliposomes: preventive efficacy against hypercholesterolemia and atherosclerosis
by: Amir Abbas Momtazi-Borojeni, et al.
Published: (2021-03-01) -
Egyptian Association of Vascular Biology and Atherosclerosis (EAVA) consensus on the usage of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors
by: Ashraf Reda, et al.
Published: (2020-05-01) -
Current treatment of dyslipidaemia: PCSK9 inhibitors and statin intolerance
by: Konstantinos Koskinas, et al.
Published: (2016-07-01) -
Subclinical Atherosclerosis in Primary Sjögren's Syndrome: Does Inflammation Matter?
by: Elena Bartoloni, et al.
Published: (2019-04-01) -
Inclisiran—Safety and Effectiveness of Small Interfering RNA in Inhibition of PCSK-9
by: Łukasz Wołowiec, et al.
Published: (2023-01-01)